載入中
Septerna, Inc., a clinical-stage biotechnology company, discovers and develops G protein-coupled receptor (GPCR) oral small molecule products for the treatment of endocrinology, immunology and inflammation, and metabolic diseases. It develops PTH1R Program, oral small molecule Parathyroid Hormone 1 Receptor agonists for the treatment of hypoparathyroidism; SEP-631, an oral small molecule MRGPRX2 negative allosteric modulator (NAM) for chronic spontaneous urticaria and other mast cell diseases; and TSHR Program, an oral small molecule TSHR NAM for graves’ disease and thyroid eye disease. In addition, it focuses on other therapeutic areas, including neurology, women’s health, cardiovascular disease, and respiratory disease. It has global collaboration and license agreement with Novo Nordisk to discover, develop and commercialize multiple potential oral small molecule therapies for metabolic-related diseases based on certain specified molecular targets. The company was formerly known as GPCR NewCo, Inc. and changed its name to Septerna Inc. in June 2021. Septerna, Inc. was incorporated in 2019 and is headquartered in South San Francisco, California.
前收盤價
US$38.37
+US$1.47 · +3.98%
盤中時間採用ET。市場資料可能有所延遲。
Septerna, Inc., a clinical-stage biotechnology company, discovers and develops G protein-coupled receptor (GPCR) oral small molecule products for the treatment of endocrinology, immunology and inflammation, and metabolic diseases. It develops PTH1R Program, oral small molecule Parathyroid Hormone 1 Receptor agonists for the treatment of hypoparathyroidism; SEP-631, an oral small molecule MRGPRX2 negative allosteric modulator (NAM) for chronic spontaneous urticaria and other mast cell diseases; and TSHR Program, an oral small molecule TSHR NAM for graves’ disease and thyroid eye disease. In addition, it focuses on other therapeutic areas, including neurology, women’s health, cardiovascular disease, and respiratory disease. It has global collaboration and license agreement with Novo Nordisk to discover, develop and commercialize multiple potential oral small molecule therapies for metabolic-related diseases based on certain specified molecular targets. The company was formerly known as GPCR NewCo, Inc. and changed its name to Septerna Inc. in June 2021. Septerna, Inc. was incorporated in 2019 and is headquartered in South San Francisco, California.
日內區間
目前US$38.37
52週區間
目前US$38.37
盤中時間採用ET。市場資料可能有所延遲。
Septerna, Inc., a clinical-stage biotechnology company, discovers and develops G protein-coupled receptor (GPCR) oral small molecule products for the treatment of endocrinology, immunology and inflammation, and metabolic diseases. It develops PTH1R Program, oral small molecule Parathyroid Hormone 1 Receptor agonists for the treatment of hypoparathyroidism; SEP-631, an oral small molecule MRGPRX2 negative allosteric modulator (NAM) for chronic spontaneous urticaria and other mast cell diseases; and TSHR Program, an oral small molecule TSHR NAM for graves’ disease and thyroid eye disease. In addition, it focuses on other therapeutic areas, including neurology, women’s health, cardiovascular disease, and respiratory disease. It has global collaboration and license agreement with Novo Nordisk to discover, develop and commercialize multiple potential oral small molecule therapies for metabolic-related diseases based on certain specified molecular targets. The company was formerly known as GPCR NewCo, Inc. and changed its name to Septerna Inc. in June 2021. Septerna, Inc. was incorporated in 2019 and is headquartered in South San Francisco, California.
日內區間
目前US$38.37
52週區間
目前US$38.37
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 |
|---|---|---|---|
| 營收 | 4595.1萬 USD | 107.5萬 USD | 15.1萬 USD |
| 毛利 | 4595.1萬 USD | 107.5萬 USD | 15.1萬 USD |
| 研究與開發 | 9758.4萬 USD | 6533.7萬 USD | 3597.9萬 USD |
| 銷售、一般及管理費用 | 2916.4萬 USD | 1656.1萬 USD | 972.2萬 USD |
| 營業費用 | 1.27億 USD | 8189.8萬 USD | −192.4萬 USD |
| 利息收入 | 1953萬 USD | 861.7萬 USD | 278.6萬 USD |
| 折舊和攤銷 | 160.4萬 USD | 140.1萬 USD | 84.8萬 USD |
| 營業利益 | −8079.7萬 USD | −8082.3萬 USD | 207.5萬 USD |
| 淨利 | −4887.9萬 USD | −7179.8萬 USD | 418萬 USD |
公司資料更新於 2026年10月12日。
近期已公布業績
近期已公布業績
第三方分析師預期可能變動，並非 GoAI 建議。
平均目標
US$50.40
上漲空間 31.35%報告持有此股票曝險的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI3539.04萬0.00%2.3兆 USD0.03%US$381.94+0.63%
iShares Russell 2000 ETFIWM2155.64萬0.03%787.4億 USD0.19%US$278.94+0.49%
Vanguard Extended Market ETFVXF1016.98萬0.01%954億 USD0.05%US$235+0.80%
State Street SPDR S&P Pharmaceuticals ETFXPH852.46萬1.85%4.62億 USD0.35%US$64.65+1.60%
First Trust Small Cap Growth AlphaDEX FundFYC838.67萬0.62%13.49億 USD0.70%US$115.36+1.35%
iShares Biotechnology ETFIBB834.48萬0.08%108.2億 USD0.44%US$206.49+3.00%
iShares Russell 2000 Growth ETFIWO496.86萬0.04%139.17億 USD0.24%US$356.78+0.94%
Vanguard Russell 2000 ETFVTWO485.18萬0.03%180億 USD0.06%US$112.66+0.50%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFState Street SPDR S&P Pharmaceuticals ETFXPHFirst Trust Small Cap Growth AlphaDEX FundFYCiShares Biotechnology ETFIBBiShares Russell 2000 Growth ETFIWOVanguard Russell 2000 ETFVTWOAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
